Press Release

G2GBio has the best subject matter experts in the field of the injectable drug development.

G2GBIO signs agreement with China's UBT to evaluate 'sustained-effective injectable' development platform
2026.10.23
HIT 693

G2GBIO signs agreement with China's UBT to evaluate 'sustained-effective injectable' development platform




China's UBT out-licenses obesity treatment candidate to Novo Nordisk

 

 


[by Yu, Suin] G2GBIO announced on October 19 that it signed a platform evaluation agreement for a novel drug candidate from Chinese pharmaceutical company United Bio Technology (UBT).


The agreement aims to assess the feasibility of developing a sustained-release injectable formulation by applying G2GBIO’s ‘InnoLAMP’ platform to a specific drug candidate provided by UBT.


UBT develops next-generation biopharmaceuticals. In March, it signed a licensing agreement with the multinational pharmaceutical company Novo Nordisk for ‘UBT251’ (development code), a candidate for treating diabetes and obesity, with an upfront payment of USD 200 million and milestone payments of USD 1.8 billion. UBT retains development and commercialization rights to ‘UBT251’ in mainland China, Hong Kong, Macau, and Taiwan.


UBT’s parent company, The United Laboratories, operates 11 production facilities manufacturing a broad range of products, including active pharmaceutical ingredients (APIs), finished pharmaceuticals, capsules, and medical devices.


“Long-acting injectables developed using the InnoLAMP platform have been validated by numerous global companies. We expect the evaluation to be completed ahead of schedule,” a G2GBIO official said.


On the other hand, G2GBIO disclosed a research collaboration with a European multinational pharmaceutical company in September. In March this year, the company also signed a three-party agreement with Samsung Bioepis and Epis NexLab to develop a long-acting obesity treatment and secure the underlying platform technology.